Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 52Carcinoma, Renal Cell 47Neoplasm Metastasis 24Neoplasms 18Kidney Neoplasms 18Neuroendocrine Tumors 17Carcinoma, Non-Small-Cell Lung 13Tuberous Sclerosis 12Stomach Neoplasms 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Recurrence 10Prostatic Neoplasms 10Lymphoma 10Hodgkin Disease 10Glioblastoma 10Colorectal Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Brain Neoplasms 9Lymphoma, Follicular 8Lung Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma 8Waldenstrom Macroglobulinemia 7Triple Negative Breast Neoplasms 7Sarcoma 7Multiple Myeloma 7Lymphoma, B-Cell, Marginal Zone 7Glioma 7Central Nervous System Neoplasms 7

Interventions

Trastuzumab 2Octreotide 2Leucovorin 2tipifarnib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Temozolomide 1Sorafenib 1Salts 1Oxaliplatin 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Fluorouracil 1Floxuridine 1Fentanyl 1Everolimus 1Disulfides 1Capecitabine 1Bevacizumab 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Vipoma × Everolimus × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡